VERA logo

VERA THERAPEUTICS INC

VERANASDAQ
๐Ÿ† #1762 by market capEarnings Feb 24 ยท PostUS Equity
โ€”โ€”
Quote unavailable
๐Ÿ””
Track VERA
Get earnings, price moves & breaking news on Telegram
Track
24hโ€”
7dโ€”
14dโ€”
30dโ€”
ytdโ€”
1yโ€”
๐ŸฆMarket Cap
$2.23B
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
โ€”
๐Ÿ“ŠGross Margin
โ€”
๐Ÿ’ตFCF Margin
โ€”
โš–๏ธP/S Ratio
โ€”
Otter Score
โ€”
Insufficient data
No chart data available for VERA.

Trading Snapshot

Day Range
โ€”
52-Week Range
$25.34 โ€“ $56.05
Volume (shares)
โ€”
Avg Volume (shares)
โ€”
Shares Outstanding
72.1M
Next Earnings
2027-02-24

Fundamentals Snapshot

Annual Revenue
โ€”
Last Q Revenue
โ€”
P/E Ratio
โ€”
P/S Ratio
โ€”
EPS (TTM)
$-5.90
Dividend Yield
โ€”
VERA logo

VERA THERAPEUTICS INC

VERA
Financial Trends

Financial history unavailable.

StockOtter ยท stockotter.space

About VERA THERAPEUTICS INC

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Insufficient data
โ€”/100

Analyst Ratings

โ“˜
Consensus
Buy
20 analysts
Strong Buy7
Buy10
Hold3
Sell0
Strong Sell0
Ratings as of Nov 2026

Latest News & Updates

News unavailable.